ANNGEEN
AnnGeen has comprehensively deployed the field of molecular diagnosis of genetic diseases. Their biology focuses on the project research and clinical application of cardiovascular diseases, hematological tumors, solid tumors, preimplantation genetic screening and diagnosis, monogenic disease diagnosis and other genetic diseases, and is committed to providing the most personalized precision medical testing.
ANNGEEN
Industry:
Biopharma Biotechnology Therapeutics
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.anngeen.com
Status:
Active
Contact:
+86 10 5849 9280
Similar Organizations
BioShai
BioShai is a simple blood test for the early diagnosis of Parkinson's disease.
BMR Solutions
BMR Solutions is a therapeutics company that specializes in chemotherapy and irradiation on associated with hematological disorders.
VelaVigo
VelaVigo is a start-up company engaged in macromolecular biopharmaceutical.
Official Site Inspections
http://www.anngeen.com
- Host name: 154.8.143.245
- IP address: 154.8.143.245
- Location: China
- Latitude: 39.9289
- Longitude: 116.3883
- Timezone: Asia/Shanghai
More informations about "AnnGeen"
北京安智因生物技术有限公司--首页
全国实体肿瘤体细胞突变高通量测序检测室间质量评价计划，是保证各临床实验室检测质量的重要手段。该室间质量评价计划可以确定参评实验室实体肿瘤体细胞突变高通量测序检测的能力； …See details»
AnnGeen - Crunchbase Company Profile & Funding
AnnGeen has comprehensively deployed the field of molecular diagnosis of genetic diseases. Their biology focuses on the project research and clinical application of cardiovascular …See details»
北京安智因生物技术有限公司--产品服务 - anngeen.com
北京安智因生物技术有限公司成立于2017年，是一家致力于应用高通量基因测序技术，为临床医学服务提供整体解决方案的创新 ...See details»
Anngeen Company Profile 2024: Valuation, Funding & Investors
Anngeen General Information Description. Developer and researcher of high-throughput gene sequencing technology. The company develops comprehensive solutions for the detection and …See details»
安智因生物-动脉网 - vbdata.cn
Sep 13, 2017 安智因是一家致力于高通量基因测序技术、为临床医学提供整体解决方案的创新型企业，专注于高通量测序临床服务。安智因生物是是国内首批将基因测序技术实现临床应用转 …See details»
Beijing Anngeen Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Beijing Anngeen Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 literature.See details»
北京安智因生物技术有限公司--新闻中心--详情页
May 11, 2024 近日，2024未来医疗100强榜单发布，安智因生物凭借在心血管疾病精准诊断领域持续且领先的综合实力表现，连续三年荣登主榜，获“中国医疗与健康创新服务榜top100”殊荣 …See details»
Anngeen Technologies - Products, Competitors, Financials, …
About Anngeen Technologies. Anngeen Technologies applies basic sequencing technology within the healthcare services sector. The company provides clinical testing services, including …See details»
Beijing Anngeen Biotechnology Co., Ltd. - synapse.zhihuiya.com
了解Beijing Anngeen Biotechnology Co., Ltd. (北京安智因生物技术有限公司)公司的药物管线，治疗领域，技术平台，以及它的。See details»
AnnGeen - Crunchbase
AnnGeen has comprehensively deployed the field of molecular diagnosis of genetic diseases.See details»
安智因 | 项目信息-36氪
安智因是一家致力于高通量基因测序技术、为临床医学提供整体解决方案的创新型企业，专注于高通量测序临床服务。安智因拥有雄厚的临床应用开发经验和专业的数据分析平台，汇集了国内 …See details»
Anngeen - Company, China - SWFI - Sovereign Wealth Fund Institute
Anngeen: Company in China, Asia. Anngeen is a Company located in China, Asia, and was founded in 2017. Request Profile Update; Download DataSee details»
AnnGeen: Drug pipelines, Patents, Clinical trials - Synapse
Jun 20, 2023 Explore AnnGeen with its drug pipeline, therapeutic area, technology platform, .See details»
Anngeen Asset Profile | Preqin
Based in Beijing, China and established in 2017, Anngeen operates as a biotechnology company that focuses on providing disease detection services for clinical medicine via utilizing gene …See details»
北京安智因生物技术有限公司--新闻中心 - anngeen.com
全国实体肿瘤体细胞突变高通量测序检测室间质量评价计划，是保证各临床实验室检测质量的重要手段。该室间质量评价计划可以确定参评实验室实体肿瘤体细胞突变高通量测序检测的能力； …See details»
MGI and Anngeen Form Strategic Cooperation to Empower
On December 20 th, 2021, MGI and signed a strategic cooperation agreement with Beijing Anngeen Technology (Anngeen) in Beijing.Under the agreement, MGI and the Anngeen will …See details»
Anngeen Technolgies Raises $14 Million for Clinical Genetic …
Feb 19, 2020 Anngeen Technologies of Beijing raised more than $14 million in a Series B financing to support its gene sequencing services for clinical diagnosis. The company has set …See details»
北京安智因生物技术有限公司--新闻中心--详情页
摘要. 由DMD基因变异所致的肌营养不良病的表型分类包括Duchenne型肌营养不良、Becker型肌营养不良以及 DMD 相关的扩张型心肌病。随着基因检测技术的发展以及基因筛查、尤其是扩 …See details»
YGOrganization | Yu-Gi-Oh! news that ends misinformation
1 day ago YGOrganization is the world’s most reliable information source for all Yu-Gi-Oh! news and content.See details»
北京安智因生物技术有限公司--新闻中心--详情页
心血管疾病是国人健康的“头号杀手”。 据《中国心血管健康与疾病报告2022》显示数据，我国心血管疾病患者达3.3亿，每5例死亡中就有2例死于心血管疾病。See details»